BiotonS.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2004-08-02
Share capital
8 586 420,00 PLN
Activity description

Bioton is a Polish biotechnology company that specializes in the development and production of biopharmaceuticals, particularly insulin for diabetes treatment. They provide a platform for patients to receive expert education and support regarding diabetes management. Their modern factory in Macierzysz, near Warsaw, is equipped with advanced technology for the synthesis and production of insulin.

Registered address
ul. Poznańska 12, 05-850 Macierzysz, Poland
Website
bioton.comWebsite active
Email
Email inactive
Phone
Social media
Electronic delivery address
AE:PL-71202-20543-DWAJJ-27

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Stock quotes

PLN 3.81
+0.03 (+0.79%)
3.753.803.8110:0012:0014:0016:00
Open
PLN 3.78
High
PLN 3.81
Low
PLN 3.71
Volume
19.49K
Avg. vol.
44.69K
Market cap
PLN 326.71M
P/E ratio
—
EPS
-PLN 0.10
Shares outstanding
85.86M
52-week
PLN 3.45 – 3.84
Dividend yield
—
Dividend
—
Ex dividend date
—
ISIN
PLBIOTN00029
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 19.19mUSD -2.80mUSD -2.48m
Q1 2026USD 13.27mUSD -1.09mUSD -1.39m
Q4 2025USD 16.17mUSD 967.86kUSD 442.49k
Q3 2025USD 18.25mUSD 1.83mUSD 1.05m

Results for Q3 2026:Nov 10, 2026

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 73.17mMedianUSD 816.16kAverageUSD 29.28m
Net profit
This companyUSD 364.64kMedianUSD 8.96kAverageUSD 2.64m
Operating costs
This companyUSD 66.95mMedianUSD 701.47kAverageUSD 19.26m
Assets
This companyUSD 195.15mMedianUSD 800.13kAverageUSD 29.34m

Industry

Bank accounts

Registered as a VAT taxpayer on 1993-07-05. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication dateEvent
Apr 28, 2026Call to creditors

Public aid

10 public aid cases recorded, with a total value of $9,080,083.

Grant datePurposeGross amountGranting body
Jun 25, 2025
De minimis aid (in accordance with Commission Regulation 2023/2831)
—Towarzystwo Inwestycji Społeczno-Ekonomicznych S.A.
Dec 23, 2024
Aid to cover additional costs related to an exceptionally significant increase in natural gas and electricity prices as a result of the war in Ukraine
—Prezes Zarządu Narodowego Funduszu Ochrony Środowiska i Gospodarki Wodnej
Mar 21, 2024
Aid to cover additional costs related to an exceptionally significant increase in natural gas and electricity prices as a result of the war in Ukraine
—Prezes Zarządu Narodowego Funduszu Ochrony Środowiska i Gospodarki Wodnej

European Funds

StartProjectEU co-financingProgramme
2016-08-24
Opracowanie innowacyjnej technologii wytwarzania krótko i długodziałających analogów insuliny mających zastosowanie w terapii cukrzycy.
$5,322,824Program Operacyjny Inteligentny Rozwój

Tenders

No recorded participation in tenders.

Regulatory authorisations

AuthorityTypeStatus
BDO
BDO register entry Active

Authorized Representatives

Romuald Apollo Harwas — Management Board Member
Kamila Helena Muśnicka — Attorney-in-fact (joint)
Jeremy James Launders — President of the Management Board

Manner of representation

If the management board is a one-person management board, the company is represented by one member of the management board. If the management board is a multi-member management board, the company is represented by two members of the management board acting jointly or one member of the management board acting jointly with a commercial proxy.

Supervisory board

Nicola Cadei — Supervisory Board Member
Dariusz Roman Trzeciak — Supervisory Board Member
Jia Li — Supervisory Board Member
Jubo Liu — Supervisory Board Member
Kaiguo Xia — Supervisory Board Member

Beneficial owners

No beneficial owners recorded for the company Bioton.

Competitors

NameRevenueWebsite
Adamed PharmaS.A.$541,927,181.76adamed.com.pl
Tarchomińskie Zakłady Farmaceutyczne PolfaS.A.$102,988,448.02polfa-tarchomin.com.pl
ICN Polfa RzeszówS.A.$85,044,250.03icnpolfa.pl
Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A.$37,103,878.54biomed.pl
VipharmS.A.$30,660,173.61vipharm.pl
Przedsiębiorstwo Farmaceutyczne Farmapolsp. z o.o.$21,462,728.43farmapol.pl

Change history

DateEvent
2026-08-21Share capital change (1,717,284,000.00 PLN → 8,586,420.00 PLN)
2026-07-21PKD change (Removed: 72.11.Z, 72.19.Z, 86.90.E; Added: 32.50.B, 72.10.Z, 86.99.D)
2026-04-27Address change (Starościńska 5, 02-516, Warszawa → Ul. Poznańska 12, 05-850, Macierzysz)
2019-11-25PKD change (Removed: 85.60.Z; Added: 72.11.Z)
2015-07-09PKD change (Removed: 10.89.Z, 18.12.Z, 20.20.Z, 20.41.Z, 20.42.Z, 26.60.Z, 28.25.Z, 31.01.Z, 32.50.Z, 33.12.Z, 33.20.Z, 36.00.Z, 37.00.Z, 38.11.Z, 38.12.Z, 38.21.Z, 38.22.Z, 46.38.Z, 46.45.Z, 46.75.Z, 47.73.Z, 47.74.Z, 47.75.Z, 58.11.Z, 58.13.Z, 58.14.Z, 58.19.Z, 59.20.Z, 68.10.Z, 68.20.Z, 69.20.Z, 70.22.Z, 71.11.Z, 71.12.Z, 73.11.Z, 73.20.Z, 74.90.Z, 77.11.Z, 82.11.Z, 82.19.Z, 82.91.Z, 82.99.Z, 85.59.B)

FAQ

Last updated: 2026-08-21